Acurx Pharmaceuticals raises $4.225M in registered direct offering; reports $9.1M cash

Acurx Pharmaceuticals, Inc.

Gross proceeds of ~$4.225M from sale of 1,289,980 shares/pre-funded warrants at $3.25 (institutional) and $3.80 (executives).
Concurrent private placement of Series A and B warrants to purchase up to 1,289,980 shares each; exercisable starting 6 months.
Preliminary cash and equivalents $9.1M as of June 30, 2022 (unaudited).
Board granted one-time waiver of Insider Trading Policy to let CEO, Executive Chairman, and director participate in the offering.
Net proceeds for general corporate purposes; closing expected July 27, 2022.

item 1.01 item 2.02 item 3.02 item 5.05 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.